Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drug Trials Should Be Shorter, Have Broader Endpoints, PhRMA Says

Executive Summary

The Pharmaceutical Research & Manufacturers of America is asking FDA to change its guidance on the development of weight loss drugs to allow shorter trials
Advertisement

Related Content

FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.
Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.
FDA Seeks Comparative Trials, Public Relations Makeover For Obesity Drugs
FDA Seeks Comparative Trials, Public Relations Makeover For Obesity Drugs
Advertisement
UsernamePublicRestriction

Register

PS043984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel